Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study

Ilya Kister, Yury Patskovsky, Ryan Curtin, Jinglan Pei, Katherine Perdomo, Zoe Rimler, Iryna Voloshyna, Marie I. Samanovic, Amber R. Cornelius, Yogambigai Velmurugu, Samantha Nyovanie, Joseph Kim, Ethan Tardio, Tamar E. Bacon, Lana Zhovtis Ryerson, Pranil Raut, Rosetta Pedotti, Kathleen Hawker, Catarina Raposo, Jessica Priest, Mark Cabatingan, Ryan C. Winger, Mark J. Mulligan, Michelle Krogsgaard, Gregg J. Silverman
doi: https://doi.org/10.1101/2022.01.10.22268752

Data Availability

All data produced in the present study are available upon reasonable request to the authors and review and approval by the study sponsor and collaborator.

Back to top
Posted January 10, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study
Ilya Kister, Yury Patskovsky, Ryan Curtin, Jinglan Pei, Katherine Perdomo, Zoe Rimler, Iryna Voloshyna, Marie I. Samanovic, Amber R. Cornelius, Yogambigai Velmurugu, Samantha Nyovanie, Joseph Kim, Ethan Tardio, Tamar E. Bacon, Lana Zhovtis Ryerson, Pranil Raut, Rosetta Pedotti, Kathleen Hawker, Catarina Raposo, Jessica Priest, Mark Cabatingan, Ryan C. Winger, Mark J. Mulligan, Michelle Krogsgaard, Gregg J. Silverman
medRxiv 2022.01.10.22268752; doi: https://doi.org/10.1101/2022.01.10.22268752
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area